World’s biggest multibillionaire investor is buying THIS by the ton [picture]

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

David J. Grainger net worth and biography

David Grainger Biography and Net Worth

Insider of Centessa Pharmaceuticals

Dr. David Grainger, PhD, is Chief Innovation Officer of Centessa Pharmaceuticals. Most recently, David was a Co-Founder and Chief Scientific Advisor at Medicxi, and he will continue in a consulting capacity. He was the Chairman and CEO of several of their portfolio companies and co-founder of The Foundation Institute for 21st Century Medicine. David has co-founded 28 biotechnology companies over the course of his career.

Previously, David was a Venture Partner with Index Ventures for four years. Before joining Index, he founded Funxional Therapeutics and the out-sourced drug developers Total Scientific and RxCelerate. In addition, he led an internationally recognized research group in Cambridge University’s Department of Medicine, where he published more than 80 first author papers in leading journals including Nature, Science and Nature Medicine. David has written extensively on the subject of optimizing structures for pharmaceutical R&D at both DrugBaron.com and Forbes.com.

David has over 150 patents and patent applications in his name and holds MA and PhD degrees in Natural Sciences from the University of Cambridge.

How do I contact David J. Grainger?: The corporate mailing address for Dr. Grainger and other Centessa Pharmaceuticals executives is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. Centessa Pharmaceuticals can also be reached via phone at 44-73-9178-9784 and via email at [email protected]. Learn More on David J. Grainger's contact information.
Has David J. Grainger been buying or selling shares of Centessa Pharmaceuticals?: David J. Grainger has not been actively trading shares of Centessa Pharmaceuticals during the past quarter. Most recently, on Friday, January 28th, David J. Grainger bought 27,500 shares of Centessa Pharmaceuticals stock. The stock was acquired at an average cost of $9.05 per share, with a total value of $248,875.00. Learn More on David J. Grainger's trading history.
Who are Centessa Pharmaceuticals' active insiders?: Centessa Pharmaceuticals' insider roster includes Tia Bush (Insider), Francesco De Rubertis (Director), (Bermuda) Gap (Major Shareholder), David Grainger (Insider), Aaron Kantoff (Director), and Saurabh Saha (CEO). Learn More on Centessa Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Centessa Pharmaceuticals?: In the last year, insiders at the sold shares 6 times. They sold a total of 114,211 shares worth more than $972,938.86. The most recent insider tranaction occured on March, 25th when insider Karen M Anderson sold 51,160 shares worth more than $607,780.80. Insiders at Centessa Pharmaceuticals own 11.5% of the company. Learn More about insider trades at Centessa Pharmaceuticals.
Information on this page was last updated on 3/25/2024.

David J. Grainger Insider Trading History at Centessa Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/28/2022	Buy	27,500	$9.05	$248,875.00

David J. Grainger Buying and Selling Activity at Centessa Pharmaceuticals

Centessa Pharmaceuticals Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Today's Range

Now: $8.93

$8.90

$9.39

50 Day Range

MA: $10.93

$9.40

$12.20

2 Week Range

Now: $8.93

$3.96

$12.45

Volume

286,486 shs

Average Volume

373,297 shs

Market Capitalization

$895.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38